Earnings Review and Free Research Report: PerkinElmer’s Q2 Bottom-line Met Expectations; Raised Outlook
Research Desk Line-up: Agilent Technologies Post Earnings Coverage
LONDON, UK / ACCESSWIRE / August 22, 2017 /Pro-Trader Daily has just published a free post-earnings coverage on PerkinElmer, Inc. (NYSE: PKI), which can be viewed by registering at http://protraderdaily.com/optin/?symbol=PKI, following the Company's reporting of its financial results on August 03, 2017, for the second quarter fiscal 2017 (Q2 FY17). The Waltham, Massachusetts-based Company's GAAP gross margin and adjusted gross margin expanded 160 and 70 basis points, respectively. Our daily stock reports are accessible for free, and with those to look forward today you also will be signing up for a complimentary member's account at:
Get more of our free earnings reports coverage from other constituents of the Medical Laboratories & Research industry. Pro-TD has currently selected Agilent Technologies, Inc. (NYSE: A) for due-diligence and potential coverage as the Company reported on August 15, 2017, its financial results for Q3 FY17 which ended on July 31, 2017. Register for a free membership today, and be among the early birds that get access to our report on Agilent Technologies when we publish it.
At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on PKI; also brushing on A. With the links below you can directly download the report of your stock of interest free of charge at:
For the three months ended on July 02, 2017, PerkinElmer reported revenues of $546.96 million, up 2% from $536.24 million recorded at the end of Q2 FY16. However, total revenues numbers for the reported quarter fell short of market expectations of $552.3 million. The Company recorded an organic growth of 1% during Q2 FY17.
The scientific instruments maker reported income from continuing operations of $62.73 million, or $0.57 per diluted share, in Q2 FY17 compared to $57.76 million, or $0.53 per diluted share, in Q2 FY16. The Company's adjusted earnings came in at $0.67 per diluted share for Q2 FY17, which was above the $0.63 per diluted share reported in the prior year period. Wall Street had also expected adjusted earnings of $0.67 per diluted share for Q2 FY17.
In Q2 FY17, the Company posted adjusted gross margin of $266.8 million, or 48.8% of revenues, compared to $262.1 million, or 48.9% of revenues in the year ago same quarter. Operating income from continuing operations was $76.00 million for Q2 FY17 compared to $66.27 million in past year's corresponding period. Operating profit margin came in at 13.9% of revenue for Q2 FY17, rising from 12.4% of revenue in the year ago same quarter.
Adjusted operating income stood at $99.57 million for Q2 FY17 versus $94.10 million in the previous year's comparable period. Furthermore, adjusted operating profit margin was 18.2% of adjusted revenue for Q2 FY17 compared to 17.5% of adjusted revenue in Q2 FY16.
During Q2 FY17, Discovery & Analytical Solutions segment's revenue came in at $383.13 million compared to $381.50 million in the year ago same period. The segment reported adjusted operating income of $63.98 million in Q2 FY17 compared to $60.02 million in Q2 FY16. Additionally, the segment's adjusted operating profit margins rose to 16.7% of segment revenue in Q2 FY17 from 15.7% of segment revenues in Q2 FY16.
PerkinElmer's Diagnostics segment revenues were $163.83 million in Q2 FY17, which was 6% higher than last year's recorded revenues numbers of $154.74 million. The segment's reported adjusted operating income was $48.76 million in Q2 FY17 versus $47.27 million in Q2 FY16. Moreover, the segment's adjusted operating profit margin was 29.7% for Q2 FY17 compared to 30.5% in Q2 FY16.
Cash Flow & Balance Sheet
In the reported quarter, PerkinElmer generated $54.45 million in cash from operations of continuing operations compared to $81.15 million in the year ago same quarter. The Company had cash and cash equivalents balance of $616.31 million as on July 02, 2017, compared to $359.27 million at the close of books on January 01, 2017. Furthermore, the Company ended the quarter with long-term debt of $1.09 billion compared to $1.05 billion as on January 01, 2017.
In a separate press release on Jul 24, 2017, PerkinElmer's Board of Directors declared a quarterly cash dividend of $0.07 per share of common stock. The dividend is payable on November 10, 2017, to all shareholders of record at the close of business on October 20, 2017.
For full FY17, PerkinElmer updated GAAP earnings per share from continuing operations to a new range of $2.23 to $2.31. Furthermore, on a non-GAAP basis, adjusted earnings are now forecasted to be between $2.84 to $2.92 per share.
On Monday, August 21, 2017, the stock closed the trading session at $64.15, climbing 1.07% from its previous closing price of $63.47. A total volume of 551.00 thousand shares have exchanged hands. PerkinElmer's stock price rallied 3.18% in the last three months, 15.25% in the past six months, and 16.00% in the previous twelve months. Furthermore, since the start of the year, shares of the Company have surged 23.01%. The stock is trading at a PE ratio of 34.40 and has a dividend yield of 0.44%. At Monday's closing price, the stock's net capitalization stands at $7.09 billion.
Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: (917) 341.4653
Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
© 2017 Accesswire. All Rights Reserved.